Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - IOVANCE BIOTHERAPEUTICS, INC. | v403564_ex31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - IOVANCE BIOTHERAPEUTICS, INC. | v403564_ex23-1.htm |
| EX-31.2 - EXHIBIT 31.2 - IOVANCE BIOTHERAPEUTICS, INC. | v403564_ex31-2.htm |
| EX-10.46 - EXHIBIT 10.46 - IOVANCE BIOTHERAPEUTICS, INC. | v403564_ex10-46.htm |
| EX-32.1 - EXHIBIT 32.1 - IOVANCE BIOTHERAPEUTICS, INC. | v403564_ex32-1.htm |
| EXCEL - IDEA: XBRL DOCUMENT - IOVANCE BIOTHERAPEUTICS, INC. | Financial_Report.xls |
| 10-K - FORM 10-K - IOVANCE BIOTHERAPEUTICS, INC. | v403564_10k.htm |
| EX-10.47 - EXHIBIT 10.47 - IOVANCE BIOTHERAPEUTICS, INC. | v403564_ex10-47.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, Michael Handelman, Chief Financial Officer of Lion Biotechnologies, Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
| • | the Annual Report on Form 10-K of the Company for the year ended December 31, 2014 (Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| • | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. |
| Date: March 16, 2015 | |||
| /s/ Michael Handelman | |||
| Michael Handelman | |||
| Chief Financial Officer | |||
| (Principal Financial Officer) | |||